Predictions of 2018 pharma M&A surge fall flat, but patent licensing deals are at a record high
Despite forecasts of a sharp rise in pharma deal-making activity, it has proved to be a slow year on the M&A front. One reason may be that licensing partnerships are proving far more popular than many had expected.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now